Kiora Pharmaceuticals appointed Keith Lane to lead clinical development and regulatory affairs, with a $350,000 salary and an option for 55,000 shares. The appointment matters because Lane’s ophthalmology development experience is intended to support the company’s pipeline and new asset opportunities, alongside a $75,000 sign-on Bonus and performance target of up to 35%.

Key Highlights

  • Keith Lane will receive a $75,000 sign-on bonus under his employment terms.
  • His performance bonus carries a target of up to 35% of annual base salary.
  • Lane previously held senior clinical and scientific roles at ophthalmology-focused Ora.

KIORA PHARMACEUTICALS INC (NASDAQ: KPRX) appointed Keith Lane as executive vice president and head of clinical development and regulatory affairs, effective September 8, 2026. The role carries an annual base salary of $350,000, and Lane will serve as the company’s principal clinical development executive.

$350,000 Salary and 55,000-Share Option

The employment arrangement is at will, and the offer letter was entered into on June 22, 2026.

Clinical Experience Supports Kiora Pipeline

Lane previously served as chief scientific officer at Ora, an ophthalmology-focused clinical research organization, after holding senior clinical and therapeutic-area positions there. Kiora’s press release stated that his experience would support advancement of its pipeline and new asset opportunities. Lane will report to Chief Executive Officer Brian Strem.